MRVI

SEC source: 0000950170-25-084483 · ownership.xml · derivative · entry 2

Brust Bernd · CIK 0001380632 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Class A Common Stock · 1,000,000 shares

Expires 2035-06-08

F2 · derivative.exercise_date: Represents options awarded under the Omnibus Incentive Plan. These options vest over a three-year period, with one-third of the options vesting on the first anniversary of the grant date and the remaining two-thirds of the options vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

SEC source: 0000950170-25-084483 · ownership.xml · nonDerivative · entry 1

Brust Bernd · CIK 0001380632 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs vest over a three-year period, with one-third of the RSUs vesting on the first anniversary of the grant date and the remaining two-thirds of the RSUs vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

SEC source: 0001823239-25-000068 · wk-form4_1748469084.xml · nonDerivative · entry 1

Dolan Christine · CIK 0001684273 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 473,607

F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 2,381 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

SEC source: 0001823239-25-000069 · wk-form4_1748469145.xml · nonDerivative · entry 1

Herde Kevin · CIK 0001671595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 674,636

F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 876 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

SEC source: 0001823239-25-000051 · wk-form4_1742421453.xml · nonDerivative · entry 1

Dolan Christine · CIK 0001684273 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 471,226

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001823239-25-000041 · wk-form4_1742419594.xml · nonDerivative · entry 1

Dolan Christine · CIK 0001684273 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,677

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000056 · wk-form4_1742421504.xml · nonDerivative · entry 1

Herde Kevin · CIK 0001671595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 673,760

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001823239-25-000044 · wk-form4_1742419628.xml · nonDerivative · entry 1

Herde Kevin · CIK 0001671595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,282

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000053 · wk-form4_1742421473.xml · nonDerivative · entry 1

Leddy Peter Michael · CIK 0001332202 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 732,331

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001823239-25-000043 · wk-form4_1742419616.xml · nonDerivative · entry 1

Leddy Peter Michael · CIK 0001332202 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,853

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000055 · wk-form4_1742421494.xml · nonDerivative · entry 1

ORESHACK KURT · CIK 0001832579 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456,869

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001823239-25-000054 · wk-form4_1742421483.xml · nonDerivative · entry 1

BUZZEO REBECCA · CIK 0001970970 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 606,791

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001823239-25-000052 · wk-form4_1742421463.xml · nonDerivative · entry 1

MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,814,643

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001823239-25-000042 · wk-form4_1742419604.xml · nonDerivative · entry 1

ORESHACK KURT · CIK 0001832579 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,011

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000040 · wk-form4_1742419582.xml · nonDerivative · entry 1

BUZZEO REBECCA · CIK 0001970970 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 310,933

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000023 · wk-form4_1740001497.xml · nonDerivative · entry 1

Dolan Christine · CIK 0001684273 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,013

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000022 · wk-form4_1740001486.xml · nonDerivative · entry 1

Herde Kevin · CIK 0001671595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,930

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000024 · wk-form4_1740001508.xml · nonDerivative · entry 1

ORESHACK KURT · CIK 0001832579 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,590

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000018 · wk-form4_1738365624.xml · nonDerivative · entry 1

ORESHACK KURT · CIK 0001832579 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,618

F1 · shares: The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024.

SEC source: 0001823239-25-000014 · wk-form4_1737148739.xml · nonDerivative · entry 1

BURCH ANDREW · CIK 0001970770 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 369,183

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000011 · wk-form4_1737148704.xml · nonDerivative · entry 1

Dolan Christine · CIK 0001684273 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,634

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000015 · wk-form4_1737148752.xml · nonDerivative · entry 1

Herde Kevin · CIK 0001671595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,256

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000010 · wk-form4_1737148693.xml · nonDerivative · entry 1

Leddy Peter Michael · CIK 0001332202 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,739

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000016 · wk-form4_1737148764.xml · nonDerivative · entry 1

MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 828,449

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000013 · wk-form4_1737148728.xml · nonDerivative · entry 1

BUZZEO REBECCA · CIK 0001970970 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,247

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-25-000012 · wk-form4_1737148716.xml · nonDerivative · entry 1

ORESHACK KURT · CIK 0001832579 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,618

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-24-000130 · wk-form4_1734472004.xml · nonDerivative · entry 1

ECKERT R ANDREW · CIK 0001210525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,409

F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon Vesting. One-third (1/3) of the RSUs shall be fully vested upon the date of grant, and the remaining RSUs shall vest in two equal installments on the date of the 2025 Annual Meeting of Shareholders of the Company (the "2025 Annual Meeting Date") and the one-year anniversary of the 2025 Annual Meeting Date.

SEC source: 0001823239-24-000128 · wk-form4_1733782706.xml · nonDerivative · entry 2

LUCIER GREGORY T · CIK 0001251299 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Partnership

Disclosed balance after: 20,645

F1 · shares: Represents shares gifted by the Reporting Person to a family partnership, the partners of which include a trust for the benefit of the reporting person. The reporting person's spouse serves as the general partner of the partnership, and in such capacity, may have voting and dispositive power over all of such shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0001823239-24-000128 · wk-form4_1733782706.xml · nonDerivative · entry 1

LUCIER GREGORY T · CIK 0001251299 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,123

F1 · shares: Represents shares gifted by the Reporting Person to a family partnership, the partners of which include a trust for the benefit of the reporting person. The reporting person's spouse serves as the general partner of the partnership, and in such capacity, may have voting and dispositive power over all of such shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0001823239-24-000122 · wk-form4_1731965544.xml · nonDerivative · entry 1

BUZZEO REBECCA · CIK 0001970970 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,703

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-24-000120 · wk-form4_1731619922.xml · nonDerivative · entry 1

DeFord John A · CIK 0001403373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,046

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.72 to $5.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001823239-24-000113 · wk-form4_1731448774.xml · nonDerivative · entry 1

HULL CARL · CIK 0001205465 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · Through The Hull Living Trust

Disclosed balance after: 175,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.52 to $5.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001823239-24-000112 · wk-form4_1731448762.xml · nonDerivative · entry 1

BURCH ANDREW · CIK 0001970770 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 423,595

F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,841 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

SEC source: 0001823239-24-000114 · wk-form4_1731448787.xml · nonDerivative · entry 1

Dolan Christine · CIK 0001684273 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 260,338

F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,848 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

SEC source: 0001823239-24-000117 · wk-form4_1731449889.xml · nonDerivative · entry 1

Herde Kevin · CIK 0001671595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 336,600

F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,906 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

SEC source: 0001823239-24-000115 · wk-form4_1731448798.xml · nonDerivative · entry 1

ORESHACK KURT · CIK 0001832579 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,056

F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 366 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

SEC source: 0001823239-24-000102 · wk-form4_1729110408.xml · nonDerivative · entry 1

MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 989,430

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0001823239-24-000089 · wk-form4_1721161412.xml · nonDerivative · entry 1

Leddy Peter Michael · CIK 0001332202 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,781

F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

SEC source: 0000950170-24-066799 · ownership.xml · derivative · entry 4

GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS 2, LLC · CIK 0001832794 · Director · 10% owner

GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner

GTCR FUND XI/C LP · CIK 0001591436 · Director · 10% owner

GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner

GTCR PARTNERS XI/A&C LP · CIK 0001828028 · Director · 10% owner

GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 110,684,080

Underlying: Class A common stock · 8,409,946 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F1 · price: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F1 · derivative.exercise_date: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F1 · derivative.expiration_date: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F1 · ownership.nature: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F4 · ownership.nature: Represents Class B common stock and Common Units held directly by MLSH 1 after giving effect to the exchange of 8,409,946 Common Units (and cancellation of an equal number of shares of Class B common stock) for 8,409,946 shares of Class A common stock.

F7 · ownership.nature: MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP ("GTCR Fund XI/C") controls the board of managers of MLSH 2. GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI") control the board of managers of MLSH 1. GTCR Partners XI/A&C LP ("GTCR Partners XI/A&C") is the general partner of GTCR Fund XI/C. GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of each of GTCR Co-Invest XI, GTCR Partners XI/A&C and GTCR Partners XI/B. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the Class A common stock or Class B common stock held of record by MLSH 1 and MLSH 2.

F8 · ownership.nature: Each of GTCR Partners XI/A&C, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A common stock held of record by MLSH 2. Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class B common stock held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares held of record by MLSH 1 and MLSH 2 except to the extent of his pecuniary interest therein.

SEC source: 0000950170-24-066799 · ownership.xml · nonDerivative · entry 3

GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS 2, LLC · CIK 0001832794 · Director · 10% owner

GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner

GTCR FUND XI/C LP · CIK 0001591436 · Director · 10% owner

GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner

GTCR PARTNERS XI/A&C LP · CIK 0001828028 · Director · 10% owner

GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 20,150,005

F5 · shares: Represents (i) 8,409,946 shares of Class A common stock sold by MLSH 1 and (ii) 1,531,028 shares of Class A common stock sold by Maravai Life Sciences Holdings 2, LLC ("MLSH 2").

F6 · balance_after: Represents 20,150,005 shares of Class A common stock held directly by MLSH 2.

F7 · ownership.nature: MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP ("GTCR Fund XI/C") controls the board of managers of MLSH 2. GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI") control the board of managers of MLSH 1. GTCR Partners XI/A&C LP ("GTCR Partners XI/A&C") is the general partner of GTCR Fund XI/C. GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of each of GTCR Co-Invest XI, GTCR Partners XI/A&C and GTCR Partners XI/B. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the Class A common stock or Class B common stock held of record by MLSH 1 and MLSH 2.

F8 · ownership.nature: Each of GTCR Partners XI/A&C, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A common stock held of record by MLSH 2. Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class B common stock held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares held of record by MLSH 1 and MLSH 2 except to the extent of his pecuniary interest therein.

SEC source: 0000950170-24-066799 · ownership.xml · nonDerivative · entry 2

GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS 2, LLC · CIK 0001832794 · Director · 10% owner

GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner

GTCR FUND XI/C LP · CIK 0001591436 · Director · 10% owner

GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner

GTCR PARTNERS XI/A&C LP · CIK 0001828028 · Director · 10% owner

GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 30,090,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F1 · price: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F7 · ownership.nature: MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP ("GTCR Fund XI/C") controls the board of managers of MLSH 2. GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI") control the board of managers of MLSH 1. GTCR Partners XI/A&C LP ("GTCR Partners XI/A&C") is the general partner of GTCR Fund XI/C. GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of each of GTCR Co-Invest XI, GTCR Partners XI/A&C and GTCR Partners XI/B. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the Class A common stock or Class B common stock held of record by MLSH 1 and MLSH 2.

F8 · ownership.nature: Each of GTCR Partners XI/A&C, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A common stock held of record by MLSH 2. Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class B common stock held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares held of record by MLSH 1 and MLSH 2 except to the extent of his pecuniary interest therein.

SEC source: 0000950170-24-066799 · ownership.xml · nonDerivative · entry 1

GTCR INVESTMENT XI LLC · CIK 0001827977 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS, LLC · CIK 0001833157 · Director · 10% owner

MARAVAI LIFE SCIENCES HOLDINGS 2, LLC · CIK 0001832794 · Director · 10% owner

GTCR FUND XI/B LP · CIK 0001591435 · Director · 10% owner

GTCR FUND XI/C LP · CIK 0001591436 · Director · 10% owner

GTCR CO-INVEST XI LP · CIK 0001591432 · Director · 10% owner

GTCR PARTNERS XI/A&C LP · CIK 0001828028 · Director · 10% owner

GTCR PARTNERS XI/B LP · CIK 0001827959 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 110,684,080

F1 · kind: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F1 · price: Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.

F2 · balance_after: Represents 110,684,080 shares of Class B common stock held directly by MLSH 1.

F3 · ownership.nature: Shares of Class B common stock confer no economic rights on the holders thereof. Except as provided in the Issuer's Amended and Restated Certificate of Incorporation or as otherwise required by applicable law, holders of Class B common stock will be entitled to one vote per share on all matters to be voted on by holders of the Issuer's Class A common stock. Upon exchange of Common Units that are held by MLSH 1 and reported in Table II hereof, an equal number of shares of Class B common stock will be delivered to the Issuer and cancelled for no consideration.

F4 · ownership.nature: Represents Class B common stock and Common Units held directly by MLSH 1 after giving effect to the exchange of 8,409,946 Common Units (and cancellation of an equal number of shares of Class B common stock) for 8,409,946 shares of Class A common stock.

F7 · ownership.nature: MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP ("GTCR Fund XI/C") controls the board of managers of MLSH 2. GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI") control the board of managers of MLSH 1. GTCR Partners XI/A&C LP ("GTCR Partners XI/A&C") is the general partner of GTCR Fund XI/C. GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of each of GTCR Co-Invest XI, GTCR Partners XI/A&C and GTCR Partners XI/B. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the Class A common stock or Class B common stock held of record by MLSH 1 and MLSH 2.

F8 · ownership.nature: Each of GTCR Partners XI/A&C, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A common stock held of record by MLSH 2. Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class B common stock held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares held of record by MLSH 1 and MLSH 2 except to the extent of his pecuniary interest therein.

SEC source: 0001823239-24-000077 · wk-form4_1716587895.xml · nonDerivative · entry 1

Ashkenazi Anat · CIK 0001761679 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,768

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

SEC source: 0001823239-24-000073 · wk-form4_1716587848.xml · nonDerivative · entry 1

DeFord John A · CIK 0001403373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,546

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

SEC source: 0001823239-24-000080 · wk-form4_1716587920.xml · nonDerivative · entry 1

MIHAS CONSTANTINE S · CIK 0001262930 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,916

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

F2 · balance_after: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

SEC source: 0001823239-24-000071 · wk-form4_1716587801.xml · nonDerivative · entry 1

LUCIER GREGORY T · CIK 0001251299 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,768

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

SEC source: 0001823239-24-000075 · wk-form4_1716587874.xml · nonDerivative · entry 1

Hopfield Jessica · CIK 0001648715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,768

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

SEC source: 0001823239-24-000079 · wk-form4_1716587911.xml · nonDerivative · entry 1

CUNNINGHAM SEAN LAURENCE · CIK 0001829753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,916

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

F2 · balance_after: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

SEC source: 0001823239-24-000078 · wk-form4_1716587903.xml · nonDerivative · entry 1

PRAHALAD MURALI · CIK 0001829991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,468

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

SEC source: 0001823239-24-000076 · wk-form4_1716587885.xml · nonDerivative · entry 1

DAVERMAN BENJAMIN JAMES · CIK 0001829768 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,916

F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

F2 · balance_after: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.